Open AccessRelating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
Author(s) -
Wong Martin C.S.,
Wong Sunny,
Huang Junjie,
Yan Bryan
Publication year - 2020
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.12952
Subject(s) - medicine , discontinuation , covid-19 , angiotensin receptor blockers , angiotensin converting enzyme , incidence (geometry) , perspective (graphical) , intensive care medicine , critical appraisal , angiotensin ii , disease , pharmacology , receptor , virology , infectious disease (medical specialty) , alternative medicine , pathology , physics , artificial intelligence , outbreak , computer science , blood pressure , optics
The present Perspective examined the latest evidence on the association between the use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID‐19). Our critical appraisal from existing literature does not support discontinuation of ACEIs/ARBs in clinical practice as there is absence of solid evidence. However, we do recommend future research perspective in formulation and implementation of practice‐changing guidelines.